Toute l’actualité d’OTR3
News | Non classé
Nous sommes ravis de présenter, à l'occasion du congrès ESTIV 2024 à Prague, un poster et une présentation orale sur notre projet MAT-PL (ANR-MAT-PL/ANR-22-CE18-0013), en collaboration avec PKDERM, sur "SUCCESSFUL GENERATION OF THREE-DIMENSIONAL HUMAN PRECISION-CUT LUNG SLICES FOR PULMONARY FIBROSIS MODELING". ESTIV_00118[74]
DERMAPLIQ | Media Publications
Abstract: This study aimed to compare incisional wound healing in cats and dogs after the topical application of Manuka honey and a new medical device, Dermapliq. Comparisons were made between each treatment and control, between the two treatments, and between dogs and cats. Twelve cats and twelve dogs were [...]
CLERAPLIQ
Clerapliq - Topical Treatment with a New Matrix Therapy Agent Abdelouahab Aifa, Julie Gueudry, Alexandre Portmann, Agn`es Delcampe, and Marc Muraine PURPOSE. Neurotrophic keratopathy is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, possibly leading to perforation. We aimed to assess the efficacy and tolerance [...]
CLERAPLIQ
Clerapliq -Prise en charge médicale des ulcères cornéens avec RGTA Cas clinique - L'Essentiel Bertrand Michaud - Docteur vétérinaire Les ulcères cornéens sont des affections fréquemment rencontrées en pratique vétérinaire quotidienne. Leur trai- tement passe par la mise en évidence de l’origine de la lésion. Ainsi, le traitement devra [...]
News
OTR3 announces first patient enrolled in a Phase I study of OTR4132-MD in Acute Ischemic Stroke (AIS).
News
OTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..
News
OTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.